EuMentis Therapeutics is dedicated to utilizing clinically validated science and cutting-edge technology to enhance the quality of life for individuals dealing with serious neuropsychiatric conditions. By merging established knowledge on glutamate and dopamine dysregulation with innovative precision medicine techniques, EuMentis Therapeutics strives to develop groundbreaking therapies that restore neural balance.
Driven by a mission to revolutionize treatment options, the team at EuMentis Therapeutics leverages their extensive experience in therapy development and company building to collaborate with experts and advocate organizations. Focusing on pediatric neuropsychiatric conditions with limited treatment options, their first medication in progress, EM-221 for Tourette syndrome, aims to mitigate excessive dopamine signaling associated with motor and vocal tics, while avoiding the undesirable side effects common in existing FDA-approved medications.
Recognizing the importance of patient input, EuMentis Therapeutics places a strong emphasis on building genuine, trusting relationships with patients, families, healthcare providers, and research partners to ensure that their therapies address the real-world needs of those impacted by neuropsychiatric conditions.
Generated from the website content
